CORONA Remedies Limited has informed the Exchange regarding a press release dated January 02, 2026, titled "Press Release on financial results for Q2FY26 ".
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ahmedabad-based pharma company CORONA Remedies reported its Q2 and H1 FY26 (ended September 30, 2025) results. Revenue from operations stood at ₹361.13 Cr in Q2 (up 15.1% YoY) and ₹707.67 Cr in H1 (up 17.0% YoY), with growth said to outpace the Indian pharmaceutical market. Profit after tax rose 21.8% YoY to ₹52.32 Cr in Q2 and 35.1% YoY to ₹98.52 Cr in H1, with H1 PAT margin at 13.9% and EBITDA margin at 20.9%. The company also posted strong return ratios – annualised RoE of 31.1% and RoCE of 49.7% – with healthy cash conversion (OCF/EBITDA at 76.5%) and lean working capital of 23 days. Management credited the performance to a strengthened field force, brand portfolio expansion and focus on specialist prescriptions, and thanked bankers for the recent stock exchange listing. An earnings call is scheduled for January 5, 2026.
Broadly positive for shareholders: double-digit revenue and profit growth that beats industry growth, expanding margins and high return ratios signal a healthy franchise. The stock is likely to see a constructive short-term reaction, with the upcoming earnings call as the next catalyst.